Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3767)	10/12/1999 6:32:00 PM
From: PaulW	Read Replies (1) \| Respond to of 10280

Peter - if we take the 30% away for the first generic, the branded retains 70% for the first six months, but I have not seen a percentage on price except for the generic. At least we know it will be higher than the generic price so if we said in worst case it was the same price as the generic we know that the branded company would expect at minimum 49% of previous sales dollars (70% market share times 70% of price). If they did not discount it would be 70%. After the first six months, if there were multiple AB generics (pharmacist can change without call physician), it can get very competitive but I heard somewhere the branded target estimate was 50% of the market but have seen anything concerning price.